Related by context. All words. (Click for frequent words.) 84 phase IIa clinical 80 Phase 2b clinical 80 Phase 1b clinical 80 phase IIa 80 Phase Ib clinical 79 Phase 2b study 79 phase IIb 79 Phase 2a clinical 79 Phase IIb clinical 79 phase IIb trial 78 Phase IIIb clinical 78 Phase Ib 78 Phase #b/#a clinical 78 Phase III clinical 78 phase Ib clinical 78 oral ridaforolimus 77 Phase 2a trial 77 Phase IIa trial 77 multicenter Phase II 77 Phase IIa clinical 77 Phase Ib clinical trials 76 Phase IIb trial 76 Phase #b/#a 76 phase IIb study 76 dirucotide 76 JAK inhibitor 76 Phase Ib II 76 IMA# 76 multicenter Phase 76 APEX PD 76 alvespimycin 76 FOLOTYN ® 76 BRIM3 75 Phase Ib study 75 placebo controlled Phase 75 Amrubicin 75 Phase IIB 75 IL# PE#QQR 75 confirmatory Phase III 75 Phase IIIb 75 Phase 1b trial 75 Phase IIb trials 75 Phase IIb clinical trials 75 registrational 74 placebo controlled Phase III 74 Cloretazine ® 74 forodesine 74 Phase IIb 74 pivotal bioequivalence 74 axitinib 74 BRIM2 74 SUCCEED trial 74 phase Ib 74 Phase 1a clinical 74 Phase 2b trial 74 multicenter randomized placebo controlled 74 randomized Phase III 74 randomized controlled Phase 74 fosbretabulin 74 pivotal Phase III 74 multicenter clinical 74 MIST II 74 Phase 2b 74 lintuzumab SGN 74 lomitapide 74 phase 2a 73 randomized Phase IIb 73 Phase III randomized controlled 73 dose escalation Phase 73 elotuzumab 73 OvaRex ® MAb 73 CEQ# 73 assessing T DM1 73 ADVANCE PD 73 Phase Ia 73 Dacogen injection 73 huC# DM4 73 phase IIIb 73 Pivotal Phase III 73 evaluating tivozanib 73 Phase IIb III 73 ongoing Phase 1b 73 Cloretazine 73 Phase Ib IIa 73 TELINTRA 73 phase III ACCLAIM 73 PFO migraine 73 TELCYTA 73 double blinded placebo 73 riociguat 73 TBC# 73 Mipomersen 72 lumiliximab 72 registrational trial 72 PANVAC VF 72 Proxinium TM 72 Bicifadine 72 Phase 1b 72 BAY #-# 72 MAGE A3 ASCI 72 Phase 2b clinical trials 72 Aflibercept 72 Corlux 72 rALLy clinical trial 72 virus HCV protease inhibitor 72 AQ4N 72 placebo controlled clinical 72 oral prodrug 72 tremelimumab 72 Zenvia ™ 72 Phase III 72 trastuzumab DM1 T DM1 72 Troxatyl 72 HGS# 72 pharmacokinetic PK study 72 dose escalation clinical 72 INCB# [001] 72 AEG# 72 HGS ETR1 72 metastatic HRPC 72 PDX pralatrexate 72 ELACYT 72 trial evaluating PRX# 72 PDE4 inhibitor 72 Xanafide 72 multicenter Phase III 72 Zybrestat 72 Phase 2a 72 RSD# oral 72 IIa trial 72 Phase IIa trials 72 YONDELIS 72 ZYBRESTAT 72 ganetespib 72 Phase 2b kidney transplant 71 confirmatory clinical 71 Azedra 71 relapsed multiple myeloma 71 Phase #b/#a trial 71 selective androgen receptor modulator 71 confirmatory Phase 3 71 rNAPc2 71 OncoVEX GM CSF 71 Phase III confirmatory 71 phase IIb III 71 TMC# C# 71 Annamycin 71 metaglidasen 71 Bezielle 71 Phase III pivotal 71 EDEMA3 71 cangrelor 71 recurrent glioblastoma multiforme 71 receptor tyrosine kinase inhibitor 71 mertansine 71 relapsed refractory multiple myeloma 71 docetaxel Taxotere R 71 PEG SN# 71 Genasense ® 71 investigational pan BCR 71 elacytarabine 71 BRAF inhibitor 71 midstage studies 71 Androxal TM 71 vascular disrupting agent 71 SCH # 71 tanespimycin 71 cediranib 71 refractory chronic lymphocytic 71 double blinded randomized 71 IMPACT IMmunotherapy 71 Traficet EN 71 active comparator 71 CR# vcMMAE 71 dose escalation trial 71 placebo controlled randomized 71 nab paclitaxel 71 MKC# MKC# PP 71 CBLC# 71 EOquin TM 71 Phase IIa 71 PNP inhibitor 71 TLK# 71 prospective multicenter 71 generation purine nucleoside 71 Phase III randomized 71 lorvotuzumab mertansine 71 glufosfamide 71 Randomized Phase 71 mapatumumab 71 Phase III clinical trials 71 hypoxia activated prodrug 71 TACI Ig 71 Aurexis 70 midstage trials 70 Allovectin 7 70 diabetic neuropathic pain 70 randomized multicenter 70 Pivotal Trial 70 olaparib 70 clinical pharmacology studies 70 MEND CABG 70 fidaxomicin Phase 3 70 Phase #/#a 70 LUX Lung 70 ponatinib 70 ToGA 70 Iluvien ® 70 KRN# 70 Safinamide 70 clinical trial 70 TG MV 70 reslizumab 70 ocrelizumab 70 Fibrillex TM 70 randomized Phase 70 bicifadine 70 radiation sensitizer 70 histone deacetylase HDAC inhibitor 70 investigational monoclonal antibody 70 CHAMPION PCI 70 Ozarelix 70 HCV protease inhibitor 70 pertuzumab 70 Ceflatonin 70 Phase 1b clinical trials 70 Panzem R NCD 70 vidofludimus 70 sunitinib malate 70 Tyrima 70 targeted radiotherapeutic 70 PSN# [002] 70 IRX 2 70 UPLYSO 70 opioid induced bowel dysfunction 70 obatoclax 70 PSMA ADC 70 budesonide foam 70 NP2 Enkephalin 70 OvaRex R 70 BrachySil TM 70 RELOVAIR ™ 70 AEGR 70 midstage clinical 70 HCV NS5B polymerase 70 Omacetaxine 70 liposomal formulation 70 Prostate AdenoCarcinoma Treatment 70 PrevOnco 70 CLARITY study 70 Phase 1a 70 oral deforolimus 70 PRT# 70 ALN TTR# 70 Fx #A 70 CCX# B 70 Alocrest 70 PEP# [003] 70 CYT# potent vascular disrupting 70 Pimavanserin 70 Sym# 70 Phase III psoriasis 70 Initiate Phase 70 pivotal Phase 70 tesmilifene 70 metastatic hormone refractory 70 PERSEUS 70 Daclizumab 70 IMC A# 70 Personalized Immunotherapy 70 CA9 SCAN 70 Romidepsin 70 Phase IIa clinical trials 70 acyclovir Lauriad R 70 HCV RESPOND 2 70 dirucotide MBP# 70 ONCONASE R 70 ENDEAVOR IV 70 Tesetaxel 70 ANCHOR trial 70 EOquin 70 viral kinetic 70 Cloretazine R VNP#M 70 brivaracetam 70 seliciclib CYC# 70 severe hypercholesterolemia 70 teriflunomide 70 IMC #B 70 inhibitor RG# 70 HGS ETR2 70 octreotide implant 70 CIMZIA TM certolizumab pegol 70 dose cohort 70 vemurafenib 70 PXD# 70 cell lymphoma CTCL 69 eltrombopag 69 interferon gamma 1b 69 Azixa 69 ruxolitinib 69 Aplidin 69 Dapagliflozin 69 deforolimus 69 HuMax EGFr 69 VITAL Trial 69 lymphoma CTCL 69 VNP#M 69 subcutaneous formulation 69 dextromethorphan quinidine 69 Archexin 69 metastatic castration resistant 69 Phenoptin 69 Phase #/#a trial 69 cutaneous T cell 69 tolevamer 69 investigational humanized monoclonal antibody 69 novel VDA molecule 69 LEP ETU 69 Laquinimod 69 Asentar 69 torezolid phosphate 69 sorafenib Nexavar 69 visilizumab 69 AIM HIGH 69 AVOREN 69 SNT MC# 69 vandetanib 69 ZACTIMA 69 Phase III placebo controlled 69 Fodosine 69 ALN PCS 69 CA4P 69 MKC# MT 69 pomalidomide 69 Allovectin 7 R 69 GALNS 69 Pivotal Phase 69 crizotinib PF # 69 Factor VIIa 69 Ophena TM 69 mRCC 69 Plicera 69 MEK inhibitor 69 recurrent malignant glioma 69 cannabinor 69 ularitide 69 investigational antiplatelet agent 69 Spiegelmer ® 69 eniluracil 69 aflibercept 69 CB2 selective receptor agonist 69 antibody MAb 69 candidate CRLX# 69 GW# [003] 69 fostamatinib 69 GSK# [002] 69 trastuzumab DM1 69 initiated Phase Ib 69 QLT# 69 alvimopan 69 refractory gout 69 cetuximab Erbitux R 69 darapladib 69 Hedgehog Pathway Inhibitor 69 Elagolix 69 Intervention Effectiveness 69 SAR# [004] 69 lintuzumab 69 BR.# 69 non nucleoside inhibitor 69 bile duct tumor 69 PEG PAL 69 sapacitabine 69 Angiocept 69 Cleviprex TM clevidipine 69 Onalta ™ 69 Cannabinor 69 SinuNase 69 HuMax CD4 69 superficial bladder cancer 69 pseudobulbar affect PBA 69 Ceflatonin R 69 vosaroxin 69 ZOLINZA 69 ThermoDox R 69 bardoxolone 69 Phase IIb Trial 69 PF # [002] 69 zanolimumab 69 EDEMA4 69 registrational Phase 69 INCB# [002] 69 HCV SPRINT 69 Phase IIb kidney transplant 69 Nexavar sorafenib 69 metastatic sarcomas 69 Phase III Clinical Trial 69 GetGoal Phase III 69 APPRAISE 69 adecatumumab 69 RSR# 69 Urocidin 69 Proellex TM 69 XL# SAR# 69 AP# [003] 69 Alfimeprase 69 multicenter placebo controlled 69 Pafuramidine 69 MGd 69 volociximab 69 mTOR inhibitor 69 Microplasmin 69 velafermin 69 proteasome inhibitor 69 Phase 2b Clinical Trial 69 EVEREST II 69 Quinamed 68 IIa clinical trial 68 ZYBRESTAT TM 68 prospective randomized controlled 68 angiogenesis inhibitor 68 gefitinib Iressa 68 dose cohorts 68 randomized Phase 2b 68 unique alkylating agent 68 PRTX 68 L BLP# 68 romidepsin 68 bevacizumab Avastin ® 68 LymphoStat B TM 68 multicentre randomized 68 orally administered inhibitor 68 RE LY 68 Zerenex 68 NVA# 68 NSABP C 68 SinuNase TM 68 MIVI III 68 PRX # 68 R#/MEM # 68 EFAPROXYN 68 TRO# 68 Phase 2a clinical trials 68 metastatic renal cell carcinoma 68 PEGylated interferon beta 1a 68 blinded randomized placebo controlled 68 Fludara ® 68 NATRECOR R 68 multicenter randomized controlled 68 EndoTAG TM -1 68 pan HDAC inhibitor 68 CCR5 antagonist 68 cilengitide 68 refractory metastatic colorectal cancer 68 OHR/AVR# 68 Cetrorelix 68 Phase IIIb study 68 Ambrisentan 68 multicenter phase 68 hormone refractory prostate cancer 68 castrate resistant prostate cancer 68 Clolar ® 68 randomized blinded 68 Azedra TM 68 oral methylnaltrexone 68 including eniluracil ADH 68 Ixempra 68 CD# monoclonal antibody 68 anticancer compound 68 dasatinib Sprycel ® 68 Civacir 68 CRMD# 68 docetaxel Taxotere ® 68 telomerase inhibitor drug 68 MEND CABG II 68 Phase III Pivotal 68 ZYBRESTAT fosbretabulin 68 Vascular Wrap TM 68 omacetaxine mepesuccinate 68 relapsing multiple sclerosis 68 masked placebo controlled 68 ocular formulation 68 neratinib 68 CCX# 68 BLP# Liposome Vaccine 68 teduglutide 68 immunotherapeutic agent 68 BCIRG 68 EchoCRT 68 metastatic castrate resistant 68 LEUKINE 68 IIb clinical trial 68 randomized controlled multicenter 68 Phase III trials 68 Zenvia Phase III 68 Curaxin CBLC# 68 castration resistant prostate cancer 68 enzastaurin 68 Aurora kinase inhibitor 68 LUMINATE 68 Combination REOLYSIN R 68 candidate AQ4N 68 ISIS # 68 ALN TTR 68 EVIZON TM 68 Luveniq 68 trastuzumab emtansine T DM1 68 Targretin 68 ABSORB trial 68 INCB# [003] 68 HCD# [002] 68 OncoVEX 68 temsirolimus 68 ELND# 68 investigational drug 68 CALGB # [002] 68 EGS# 68 Exherin TM 68 erlotinib Tarceva ® 68 Dalbavancin 68 compound INCB# 68 ILUVIEN ® 68 oral rivaroxaban 68 Tocosol Paclitaxel 68 randomized multicenter Phase III 68 phase III isavuconazole 68 COMFORT II 68 synthetic retinoid 68 mGluR5 negative 68 Dasatinib 68 TASKi2 68 relapsing remitting multiple sclerosis 68 MERLIN TIMI 68 multiple ascending dose 68 dexanabinol 68 zalutumumab 68 initiate Phase 1b 68 cetuximab Erbitux 68 elagolix 68 drug ISA# 68 entinostat 68 Irinotecan 68 Tarceva TM 68 Fibrin Pad 68 Tamibarotene 68 Diabetic Macular Edema 68 Vicriviroc 68 OncoVex 68 Hepatocellular Carcinoma HCC 68 rALLy 68 SPIRIT FIRST 68 Onco TCS 68 Vernakalant 68 relapsed MM 68 RhuDex ® 68 valopicitabine 68 relapsing remitting MS RRMS 68 CIMZIA TM 68 systemic ALCL 68 PROSTVAC TM 68 PROVENGE sipuleucel T 68 Atiprimod 68 prospective randomized multicenter 68 dacetuzumab 68 catheter occlusion 68 LAF# 68 Omnitarg 68 MDV# 68 CUSTOM III 68 treatment naive genotype 68 IMPACT DCM clinical 68 candidate XP# 68 prospective randomized placebo 68 celgosivir 68 AVADO 68 SYMMETRY trial 68 PHX# 68 midstage clinical trials 68 Initiates Phase II 68 Tezampanel 67 Telcyta 67 TRANSFORMS 67 Brentuximab Vedotin SGN 67 Achieves Primary Endpoint 67 PRIMO CABG 67 PRECISE trial 67 PD LID 67 HepeX B 67 Motesanib 67 Nexavar ® 67 Ridaforolimus 67 albiglutide 67 IMPACT DCM 67 AVONEX ® 67 MEK inhibitor RDEA# 67 GLP toxicology studies 67 generation Hsp# inhibitor 67 CoFactor 67 randomized clinical 67 RG# [001] 67 ENDEAVOR III 67 HER2 positive metastatic breast 67 PrevOnco ™ 67 Drug Eluting Stent System 67 NXL# 67 REG1 67 MYDICAR ® 67 Allovectin 7 ® 67 polymerase inhibitor 67 custirsen 67 thymalfasin 67 ADAGIO study 67 evaluating T DM1 67 ATL# [001] 67 Zolinza 67 Amoxicillin PULSYS Phase III 67 LE SN# 67 Omigard 67 evaluating Actimmune 67 Alzhemed TM 67 AAG geldanamycin analog 67 ONTARGET 67 multicenter randomized Phase 67 induced macular edema 67 L Annamycin 67 prospective multicenter randomized 67 BioNumerik 67 dose escalation 67 ExTRACT TIMI 67 tiapamil 67 EmbraceAC 67 Phase 2b randomized 67 Carfilzomib 67 ORENCIA ® 67 sorafenib tablets 67 Augment Injectable 67 ENRICH trial 67 Onconase 67 Pirfenidone 67 OvaRex 67 label multicenter 67 multicenter randomized 67 randomized multicenter trial 67 tafamidis 67 depsipeptide 67 incyclinide 67 belinostat 67 Nasdaq PGNX today 67 MOZOBIL 67 MAXY alpha 67 Tanespimycin 67 glucokinase activator 67 systemic RNAi therapeutic 67 Diabetic Macular Edema DME 67 leading oral taxane 67 Sapacitabine 67 ACTEMRA TM 67 EVIZON 67 cutaneous T 67 CRLX# 67 MT# MEDI 67 evaluating REVLIMID 67 iniparib 67 multicenter randomized double 67 vinca alkaloid 67 Phase III VISTA 67 STRIDE PD 67 ThermoDox ® clinical 67 PREOS R 67 XL# XL# XL# 67 Viprinex 67 ILLUMINATE 67 II Clinical Trial 67 metastatic CRC 67 Vicinium TM 67 ofatumumab HuMax CD# 67 Iloperidone 67 nalbuphine ER 67 Locteron ® 67 eosinophilic asthma 67 GAMMAGARD 67 Meets Primary Endpoint 67 ABSORB clinical 67 pharmacokinetic PK 67 acetonide FA 67 MAA submission 67 Nasdaq HALO 67 immunomodulatory therapy 67 MyVax R 67 NO# [002] 67 BrachySil 67 dextofisopam 67 SUTENT ® 67 Stedivaze 67 investigational protease inhibitor 67 vernakalant hydrochloride 67 humanized anti 67 PREOS 67 regorafenib 67 cardio renal 67 Solazed 67 Matrix Phase 2b 67 GVAX 67 IMGN# 67 Epratuzumab 67 docetaxel chemotherapy 67 TG# [003] 67 miconazole Lauriad ® 67 Telintra 67 gemcitabine Gemzar ® 67 clinical trials 67 delivers fluocinolone acetonide FA 67 daclizumab 67 bortezomib Velcade 67 aflibercept VEGF Trap 67 Genasense ® oblimersen 67 IV NSCLC 67 ospemifene 67 ixabepilone 67 huN# DM1 67 tramiprosate Alzhemed TM 67 trastuzumab Herceptin R 67 allosteric modulator NAM 67 RGB # 67 adecatumumab MT# 67 Nanobody 67 recurrent GBM 67 Voreloxin 67 PROVENGE ® 67 VEGF receptor inhibitor 67 SEPET TM 67 Zenvia TM 67 ancrod 67 GV# [001] 67 amrubicin 67 GED aPC 67 Phase #/#a clinical 67 posaconazole 67 DAPT 67 initiated Phase 1b 67 Lu AA# 67 subcutaneously administered 67 drug eluting coronary stent 67 fallopian tube cancers 67 AIR CF1 67 BRILINTA 67 LibiGel Phase III 67 FOLFOX6 chemotherapy regimen 67 multi kinase inhibitor 67 refractory multiple myeloma 67 telomerase therapeutic 67 Perifosine 67 NV1FGF 67 sNDA submission 67 Denufosol 67 nucleoside analog 67 Nuvion 67 PS# [001] 67 GRNVAC1 67 afatinib 67 PI3K/Akt pathway inhibitor 67 Velcade bortezomib 67 Tavocept 67 leukemia AML 67 3 registrational trial 67 Virulizin ® 67 AeroLEF TM 67 PLK1 SNALP 67 familial amyloidotic polyneuropathy FAP 67 GTC recombinant human 67 KNS # 67 IND submission 67 BST CarGel R 67 Trofex 67 refractory AML 67 CLORETAZINE TM VNP#M 67 multicenter prospective 67 RSD# 67 Atrasentan 66 refractory Hodgkin lymphoma 66 novel oral anticoagulant 66 HRPC 66 Tarvacin TM 66 dose dose escalation 66 Panzem R 66 DU #b 66 rindopepimut 66 evaluating satraplatin 66 sitaxsentan 66 otelixizumab 66 Revlimid lenalidomide 66 Vilazodone 66 telaprevir VX 66 novel histone deacetylase 66 2 methoxyestradiol 66 Glufosfamide 66 Veronate 66 NASDAQ CXSP announced 66 TASKi3 66 biliary tract cancer 66 tezampanel NGX# 66 Triapine 66 Phase 1b dose escalation 66 miconazole Lauriad R 66 BrachySil ™ 66 platinum refractory 66 AVE# 66 Desmoteplase 66 Initiated Phase 66 Solazed TM 66 bosutinib 66 MT#/MEDI-# 66 MBP# [001] 66 mipomersen 66 DXL# 66 HuLuc# 66 AZILECT R 66 methylnaltrexone 66 DermaVir Patch 66 Cinquil 66 photoprotective drug 66 Myocet 66 CRD5 66 Canvaxin 66 Valsartan 66 TORISEL 66 Ophena 66 REOLYSIN ® 66 JAK2 inhibitor 66 Octreolin 66 Afatinib 66 Vectibix panitumumab 66 dose escalation study 66 lupus nephritis 66 Pivotal Study 66 LymphoStat B belimumab 66 Pemetrexed 66 satraplatin Phase 66 squalamine 66 sunitinib 66 apaziquone 66 enoximone capsules 66 retinal vein occlusion induced 66 Neuvenge 66 Temsirolimus 66 AzaSite Plus 66 Raptiva ® 66 ProSavin 66 REG1 Anticoagulation System 66 treatment naïve genotype 66 dose escalation phase 66 Diamyd ® 66 Cloretazine R 66 ENMD # 66 Tolvaptan 66 Torisel 66 Myelodysplastic Syndrome MDS 66 ALN VSP Phase 66 INSPIRE Trial Phase III 66 Telatinib 66 clinicaltrials 66 OMP #R# 66 Cethromycin 66 AIR CF2 66 6R BH4 66 decitabine 66 randomized controlled clinical 66 Ereska 66 Dacogen decitabine 66 antisense drug 66 orBec 66 varespladib 66 Genz # 66 PRIMO CABG2 66 Randomized Phase II 66 dyskinesia PD LID 66 Sorafenib HCC Assessment 66 Phase III metastatic melanoma 66 CDK inhibitor 66 eprotirome 66 Phase III Trial 66 solanezumab 66 Insegia 66 sodium Injection 66 T DM1 66 Lixivaptan 66 dalbavancin 66 IAP inhibitors 66 bendamustine 66 Darusentan 66 ketolide antibiotic 66 drug GAP #B# 66 Panzem 66 LymphoStat B 66 dexpramipexole 66 OXi# 66 GSK# [001] 66 Ketotransdel 66 GOUT 66 recurrent glioblastoma 66 sunitinib Sutent 66 drug pipeline TAFA# 66 Aryplase 66 transcriptase inhibitor NNRTI 66 European Sepsis Trial 66 investigational oral 66 Cloretazine VNP#M 66 Gabapentin GR 66 LBH# 66 Val HeFT 66 Advaxis Phase 66 cathepsin K inhibitor 66 lexidronam injection 66 Gleevec resistant 66 ritonavir boosted 66 nucleotide analog 66 tesetaxel 66 Vitaxin 66 ITAX 66 MGCD# [001] 66 VA# [002] 66 NGX# 66 clazosentan 66 investigational hepatitis C 66 Acute Ischemic Stroke 66 brentuximab vedotin SGN 66 Clinical Antipsychotic Trials 66 XYOTAX TM 66 RE LY ® 66 oral proteasome inhibitor 66 PARP inhibitor 66 Telavancin 66 Maribavir 66 JZP 66 Viramidine 66 NSABP B 66 Silodosin 66 Enzastaurin 66 bevacizumab Avastin 66 TKM ApoB 66 RezularTM 66 tasocitinib 66 ALN HPN 66 INxin 66 Catena ® 66 REVLIMID lenalidomide 66 interferon beta 1b 66 cancer neuroendocrine tumor 66 HepeX B TM 66 Xcytrin R 66 Sprycel dasatinib 66 candidate Zenvia 66 EURIDIS 66 Seliciclib 66 Medidur TM FA 66 tecarfarin 66 HQK 66 galiximab 66 vicriviroc 66 Pivotal Clinical Trial 66 Shigamabs ® 66 Phase IIb Clinical Trial 66 Blinatumomab 66 Alemtuzumab 66 occlusion PAO 66 AZX# 66 EVIZON TM squalamine lactate 66 R sorafenib tablets 66 CDP# 66 safinamide 66 tezampanel 66 Virulizin R 66 Deforolimus 66 atacicept 66 Lupuzor 66 investigational compound 66 Cintredekin Besudotox 66 Ecallantide 66 ADP receptor antagonist 66 Phase II 66 paclitaxel poliglumex 66 metastatic malignant 66 Pyridorin 66 HspE7 66 AKT inhibitor 66 Ostarine 66 EDEMA3 trial 66 PEG IFN 66 BLA filing 66 ENESTnd 66 myelofibrosis MF 66 TEMSO 66 ganaxolone 66 TOCOSOL Paclitaxel 66 Dyloject TM 66 Tykerb lapatinib 66 lapatinib Tykerb 66 Degarelix 66 mCRC